文献速递免疫规划妇幼与学校卫生

靶向常见皮肤型HPV1的嵌合L1-L2病毒样颗粒疫苗

A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1).
PubMed 文献 · Vaccine · 2026-05-18

已上市HPV疫苗由L1病毒样颗粒(VLP)组成,仅针对疫苗型别提供型别限制性保护,不覆盖引起皮肤疣的皮肤型HPV。研究以HPV16 L1 VLP为支架展示HPV1或HPV63的L2交叉中和表位RG1,在小鼠中诱导出可中和HPV1、HPV63及HPV16的功能性抗体,并保护小鼠免受HPV1杂合假病毒攻击,提示嵌合VLP是有前景的皮肤型HPV疫苗候选。

要点

  • HPV16 L1支架展示HPV1/63 L2表位RG1可组装为嵌合VLP。
  • 小鼠免疫后诱导针对HPV1、HPV63及HPV16的功能性中和抗体。
  • 16 L1-1RG1免疫血清在体内完全保护HPV1杂合假病毒攻击。

核心结论

  • 嵌合VLP是有前景的疫苗候选,可靶向常见的皮肤型HPV1并可能覆盖HPV63,有望减少HPV所致皮肤疣负担。

研究设计与样本

  • 研究以HPV16 L1 VLP为支架,在表面环展示HPV1或HPV63的L2交叉中和表位RG1,构建嵌合16 L1-1RG1与16 L1-63RG1融合蛋白并评估其组装与免疫原性。
  • 在小鼠中开展免疫原性评估,采用ELISA和假病毒(PsV)中和试验检测抗体反应,并开展体外与体内攻击保护实验。

主要发现

  • 两种嵌合融合蛋白16 L1-1RG1和16 L1-63RG1均能自组装为VLP。
  • 小鼠免疫后诱导功能性抗体反应,ELISA和PsV中和试验显示可反应并(交叉)中和HPV1与HPV63。
  • 免疫血清也能中和HPV16 PsV,提示嵌入表位后仍保留L1介导的功能性应答。
  • 免疫血清可中和从儿童足部疣分离的天然HPV1病毒颗粒,阻止其体外感染角质形成细胞。
  • 体内攻击模型中,16 L1-1RG1免疫血清保护小鼠免受HPV1杂合PsV攻击,而16 L1-63RG1血清仅提供部分保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Licensed Human Papillomavirus (HPV) vaccines are comprised of Virus-like Particles (VLP) assembled from the major capsid protein L1 and provide type-restricted protection against the incorporated vaccine types. However, they do not target cutaneous HPV types causing common, palmo-plantar and plane skin warts, which are a frequent nuisance in children and immunosuppressed individuals. Although benign, cutaneous warts can be painful, aesthetically unpleasant, recalcitrant to treatment and are a common cause of medical consultations burdening health care systems. Timely vaccination targeting cutaneous HPV types might greatly reduce incidence of cutaneous warts. HPV1 and HPV63 are closely related cutaneous types frequently found in plantar warts. Previous attempts to generate self-assembled HPV1 and HPV63 VLP as vaccine antigens by expressing L1 have been unsuccessful, contrary to many other cutaneous types. As an alternative strategy, the highly conserved N-terminus of minor capsid protein L2 can induce (cross-)neutralizing antisera that protect against experimental challenge. Thus, VLP assembled from HPV16 L1 (16 L1) were utilized as scaffold to repetitively present a L2 cross-neutralization epitope ('RG1') of HPV1 or HPV63 on 16 L1 VLP surface loops. Both chimeric 16 L1-1RG1 and 16 L1-63RG1 fusion proteins assembled into VLP. Immunizations of mice induced a functional antibody response, reacting with and (cross-)neutralizing both HPV1 and HPV63 by ELISA and Pseudovirion (PsV) neutralization assays, respectively. Immune sera also neutralized HPV16 PsV, indicating retained ability of chimeric 16 L1 VLP to induce a functional L1-mediated response despite epitope insertion. Immune sera also sterilized native HPV1 virions isolated from children's foot warts, preventing infection of keratinocytes in vitro. In an in vivo challenge model, immune sera to 16 L1-1RG1 protected mice against HPV1 hybrid PsV challenge, while sera to 16 L1-63RG1 conferred partial protection. In conclusion, chimeric VLP appear as promising vaccine candidates to target prevalent cutaneous HPV1, and possibly HPV63, with the potential to reduce the burden of HPV-induced skin warts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bettina H, Anna SJ, Reinhard K, et al. A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1). Vaccine. 2026. PMID: 42155243. doi:10.1016/j.vaccine.2026.128729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。